Patent Regulation Drops Deference To ANDA, 505(b)(2) Sponsors
Executive Summary
FDA's final rule implementing provisions of Medicare Modernization Act ‘will fuel litigation,’ attorney predicts.
You may also be interested in...
FDA ‘Monster’ Patent Reg: Brands, Generics Each Want More Options To Pick Fights
PhRMA is concerned about the agency giving deference to generic sponsors in patent use code disputes, while GPhA wants a mechanism to challenge refuse-to-receive letters.
FDA’s ‘Monster’ Proposed Rule Targets Patent Use Codes, Paragraph IV Certification
Industry has 90 days to comment on FDA’s current handling of generic challenges to brand protections.
Celebrex Generic Exclusivity Suit Could Have Broad Financial, Regulatory Reach
Appeals court says FDA violated Hatch-Waxman by awarding 180-day exclusivity solely to Teva based on reissued patent; celecoxib generics are already marketed but could step out from Pfizer-authorized status.